Neurophet to Participate in SNMMI 2025: Showcasing 'Neurophet SCALE PET' and Expanding Global Partnerships

• Showcasing brain imaging analysis solutions such as Neurophet SCALE PET, which provides SUVR values for PET tracers
• Engaging in partnering discussions with global pharma companies and exploring business development opportunities with radiopharmaceutical companies

SEOUL, South Korea, June 20, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on the 20th that it will participate in the Society of Nuclear Medicine & Molecular Imaging (SNMMI 2025) in the United States, where it will introduce key AI-based brain imaging analysis solutions.

At SNMMI 2025, Neurophet will showcase Neurophet SCALE PET, a software solution designed for the quantitative analysis of PET (Positron Emission Tomography) images. Neurophet SCALE PET utilizes both PET and MRI (Magnetic Resonance Imaging) to quantitatively analyze biomarkers labeled with PET tracers.

Quantitative analysis of PET imaging is essential for the early diagnosis and assessment of disease progression in various neurodegenerative disorders, including Alzheimer's and Parkinson's disease. PET imaging enables the measurement of brain metabolism and neurotransmitter changes, allowing for the detection of early abnormalities that are difficult to identify through structural imaging alone (e.g., MRI or CT). This facilitates the development of more personalized treatment strategies.

Neurophet SCALE PET automatically provides the SUVR (Standardized Uptake Value Ratio) values—standardized uptake ratios based on the reference uptake in tissues with stable metabolism—for various brain imaging biomarkers, including Alzheimer's disease biomarkers such as amyloid-beta and tau proteins, as well as fluorodeoxyglucose (FDG) and dopamine.

At the conference, Neurophet is to host a booth to introduce Neurophet AQUA AD, a software solution designed to support prescription decision-making, treatment monitoring, and side effect tracking for Alzheimer's disease therapies, alongside Neurophet SCALE PET. The company also plans to hold business meetings with global pharmaceutical companies and radiotracer developers to explore strategic collaborations.

"Neurophet SCALE PET is seeing high demand from global medical device companies specializing in PET imaging and PET tracers," said Jake Junkil Been, Co-CEO of Neurophet. "Through our participation in SNMMI 2025, we aim to strengthen business development collaborations with international partners in these fields."

SNMMI 2025 is a leading conference where the latest technologies and products in nuclear medicine and molecular imaging are showcased. The event will be held from June 21 to 24 (local time) in New Orleans, USA.

About Neurophet

Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".

Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.

SOURCE Neurophet